Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Canaccord Genuity Group

Canaccord Genuity Group started coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a report published on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $75.00 price objective on the stock.

Other research analysts have also issued research reports about the company. Wedbush reiterated an “outperform” rating and issued a $48.00 target price on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Maze Therapeutics in a research note on Thursday, September 24th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and a consensus target price of $64.45.

Maze Therapeutics Stock Up 7.9%

NASDAQ:MAZE opened at $29.70 on Monday. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -11.79 and a beta of 2.16. Maze Therapeutics has a one year low of $21.95 and a one year high of $53.65. The stock has a 50-day simple moving average of $26.81 and a 200 day simple moving average of $27.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). Sell-side analysts predict that Maze Therapeutics will post -2.70 EPS for the current fiscal year.

Insider Activity

In other news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider directly owned 26,250 shares in the company, valued at approximately $723,975. This represents a 22.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the completion of the sale, the chief executive officer directly owned 18,151 shares in the company, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 192,991 shares of company stock valued at $5,152,084. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maze Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its position in Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at $48,000. Quantbot Technologies LP bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth $80,000. Squarepoint Ops LLC raised its stake in shares of Maze Therapeutics by 42.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after buying an additional 5,822 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Maze Therapeutics in the second quarter valued at $200,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.